Skip to main content
Caplight Logo









EXUMA Biotech

EXUMA Biotech

Private
West Palm Beach, FloridaHealthcare & Life Scienceshttps://exumabio.com/

Last Round

Series B

Aug 20, 2026

Total Funding Raised

$97M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

EXUMA Biotech is a biotechnology company that discovers and develops CAR-T cell therapies and delivery solutions for the treatment of solid and liquid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T therapysolid tumor treatmentcell therapyGCAR platformgene-edited CAR-Toncology drug developmentin vivo cell therapyex vivo cell therapybiotech platformnext-gen immunotherapycancer immunotherapyclinical-stage biotechcell therapy manufacturingrPOC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EXUMA Biotech Comparables

Compare EXUMA Biotech with similar companies based on industry and business-model similarity.

EXUMA Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbbVie
86%
AffyImmune Therapeutics
83%
Alaya.bio
83%

EXUMA Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 20, 2026
Series B ExtensionDec 21, 2021
Series BMar 12, 2020
VC RoundJan 7, 2018
Series AJan 6, 2017

Key People

Founding team and executive leadership

Gregory Frost

Chairman & CEO

Executive Team

James Samuels

Chief Financial Officer

Executive Team

EXUMA Biotech Investors

Notable investors and investment history

EXUMA Biotech investors
InvestorRounds
SunTerra CapitalVC Round, Series A
Sinobioway GroupVC Round, Series A
BDT & MSD PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    $70M round completed.

  • Jan 23, 2025

    Presented at the ASCO GI 2025 symposium.

EXUMA Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EXUMA Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EXUMA Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersWest Palm Beach, Florida
Employee Range26
Year Founded2015
Last FundingAug 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?